<DOC>
	<DOCNO>NCT01258374</DOCNO>
	<brief_summary>While 3-drug regimen remain standard care , concern exist regard safety multi-drug regimens take lifetime . Problems nucleoside analogue therapy prompt successful trial ritonavir ( RTV ) boost PI monotherapy , however long term safety efficacy regimens remain unknown . Clinical trial show Raltegravir ( RAL ) potent activity patient active background drug ; superior lipid profile compare EFV LPV/RTV . Darunavir/r ( DRV ) potent , well tolerate PI GI side effect lipid disturbance high genetic barrier . The investigator hypothesize RAL/DRV would well tolerate effective regimen patient fail nucleoside reverse transcriptase inhibitor base regimen , due poor tolerability resistance . The investigator also would like explore plasma pharmacokinetics Raltegravir combine Darunavir sub-group 12 HIV-infected patient .</brief_summary>
	<brief_title>Dual Therapy With Raltegravir Darunavir/Ritonavir HIV Infected Patients .</brief_title>
	<detailed_description>Hypothesis - NRTI-sparing regimen attractive option avoid NRTI-associated toxicity provide full active regimen patient extent NRTI resistance . - Raltegravir ( RAL ) Darunavir ( DRV ) potent `` third drug '' provide synergistic inhibition 2 different step HIV replication . - DRV high genetic barrier , could excellent accompany drug Raltegravir , provide potent , safe well tolerate dual therapy patient fail NNRTI base treatment . Objectives : - To describe safety , tolerability efficacy combination Raltegravir Darunavir 24 week follow HIV infect patient fail NRTI base regimen . - To describe plasma pharmacokinetics Raltegravir combine Darunavir 800mg QD HIV-infected patient .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Documented HIV infection Na√Øve Raltegravir . CD4 cell count 200 cell/mm3 . No history failure PI containing regimen . No evidence PI mutation ( IASmutation list ) genotype test . Failing NRTI base regimen . The treat physician decides NRTI spar regimen include DRV/r 800/100 mg QD plus Raltegravir 400 mg BID . Signed informed consent form In opinion investigator , patient consider clinically stable could follow regular visit schedule per protocol . Patients receive drug consider contraindicate Raltegravir DRV/r . Contraindicated drug : rifampin , fenitoin , phenobarbital case raltegravir . Pravastatin , astemizole , sildenafil , contraindicate combination DRV/r . Pregnancy Documented PI mutation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Pharmacokinetics , raltegravir , darunavir , NRTI spar regimen</keyword>
</DOC>